Phase II Study of Loncastuximab Tesirine Given by IV as Consolidation Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma After CAR T-cell Therapy

What this Trial Is About

Researchers are evaluating loncastuximab tesirine called lonca as a consolidation treatment for patients with relapsed or refractory large B-cell lymphoma LBCL who have achieved a partial response after CAR T-cell therapy. This phase II study aims to assess loncas ability to control the disease in this specific patient group, while also studying its safety, tolerability, and biological effects. Participants will receive loncastuximab tesirine through an intravenous infusion. The study involves a single treatment group where lonca is administered as consolidation therapy following CAR T-cell treatment. Key eligibility includes being at least 18 years old, having a certain lymphoma subtype, and meeting specific clinical and laboratory criteria after CAR T-cell therapy. The treatment period and dosing schedules are defined by the study protocol. During the study, participants will be monitored through various assessments to evaluate treatment response, side effects, and biological markers. The main measurement is the rate at which patients convert from partial to complete response within about a year or until study completion. Safety and tolerability are closely observed, and follow-up visits are conducted to assess ongoing effects. The total study duration extends to the studys completion date, allowing comprehensive evaluation of lonca as consolidation therapy.

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy